"For more than 50 years the
More than 30 abstracts will be presented at the ASCO Annual Meeting, which is being held
- An interferon-gamma gene signature was shown to predict response more accurately than PD-L1 IHC in squamous cell carcinoma of the head and neck. This research further demonstrates the power of gene expression profiling on the nCounter Analysis System as a biomarker in immuno-oncology. (Abstract #6010)
- An interferon-gamma gene signature and an expanded immune gene signature predicted response in five tumor types from the basket trial KEYNOTE-28, underscoring the potentially broad applicability of gene signatures in assessing patient response (Abstract #1536).
- Data on the development and analytical performance of an nCounter-based assay incorporating an immune-related gene signature to predict response to checkpoint inhibition in eleven different tumor types. The data show that this assay is robust and may be well-suited to clinical applications. The signature is being evaluated as a predictive biomarker in multiple indications in several studies (Abstract #3034).
- An update
on the ongoing ROBUST trial, a global pivotal phase 3 trial evaluating the addition of lenalidomide to R-CHOP therapy in untreated
ABC-type Diffuse Large B-cell Lymphoma (DLBCL) selected by NanoString's investigational Cell-of-Origin assay. The results show that real-time testing of Cell-of-Origin using nCounter is feasible in a multi-center, global study with turnaround time of less than 3 days, demonstrating that a decentralized gene expression test can be used to select patients for a clinical trial where rapid results are critical for enrollment (Abstract #7538).
- Independent validation of the nCounter-based Cell-of-Origin assay through comparison to subtyping using DNA microarrays. The assay proved to be highly efficient and reliable in an independent series of samples evaluated by a team of researchers not involved in the development of the assay. This research
highlights the high concordance between the
NanoStringassay and the conventional microarray method as well as the robustness and ease of use of the assay, which can be successfully deployed in laboratories around the world (Abstract #7547).
The 2016 ASCO abstracts describe research and clinical applications that underscore the diverse capabilities and robust performance of the nCounter platform. The studies cover a wide range of cancers, tissue types (FFPE, peripheral blood and urine), and treatment modalities.
At the 2016 ASCO Annual Meeting,
|4525||Subclassification and outcome prediction of patients with muscle invasive urothelial carcinoma (MIUC) treated by radical cystectomy (RC) with a ||http://abstracts.asco.org/176/AbstView_176_167004.html|
|3034||Development and analytical performance of a molecular diagnostic for anti-PD1 response on the nCounter Dx Analysis System.||http://abstracts.asco.org/176/AbstView_176_168736.html|
|3008||Epigenetic control of CD4/CD8 lineage commitment and resistance to tumor infiltrating lymphocyte adoptive cell therapy for metastatic melanoma.||http://abstracts.asco.org/176/AbstView_176_170003.html|
|6056||Immune-related gene expression signatures as predictive biomarkers for outcome after concurrent chemoradiation in patients with locally advanced oropharyngeal carcinomas.||http://abstracts.asco.org/176/AbstView_176_169537.html|
|11522||Derivation of gene expression classifiers for the non-invasive detection of bladder cancer in the hematuria and recurrence surveillance populations.||
|e16014||Multiplatform comprehensive kinase analysis of muscle-invasive bladder cancer (MIBC) to identify potentially actionable therapeutic targets.||http://abstracts.asco.org/176/AbstView_176_169117.html|
|10561||Patterns of PD-1, PD-L1 and PD-L2 expression in pediatric solid tumors.||http://abstracts.asco.org/176/AbstView_176_168360.html|
|TPS3636||The FUNNEL: A molecular multiplex triage for precision medicine in metastatic colorectal cancer.||
|3038||Association of response to programmed death 1 receptor or ligand (PD1/PDL1) blockade with immune-related gene expression profiling across three cancer-types.||http://abstracts.asco.org/176/AbstView_176_170034.html|
|7045||Up-regulation of BAALC/MN1/MLLT11/EVI1 gene cluster in relation to MYC / BCL2 protein co-expression and poor overall survival in acute myeloid leukemia (AML).||http://abstracts.asco.org/176/AbstView_176_171325.html|
|e20089||Preliminary analysis of genomic profiling of small cell lung cancer in Chinese population revealed frequent PIK3CA hotspot mutations.||http://abstracts.asco.org/176/AbstView_176_171299.html|
|e23235||Analysis of RSPO gene expression in solid tumors.||http://abstracts.asco.org/176/AbstView_176_170408.html|
|e14565||Safety and immunologic activity of anakinra in HER2-negative metastatic breast cancer (MBC).||http://abstracts.asco.org/176/AbstView_176_170364.html|
|10509||Relationship of BRAF V600E and associated secondary mutations on survival rate and response to conventional therapies in childhood low-grade glioma.||http://abstracts.asco.org/176/AbstView_176_168561.html|
|e17103||Genomic profiling of high-intermediate risk endometrial cancer to differentiate recurrence risk.||http://abstracts.asco.org/176/AbstView_176_168355.html|
|3570||Influence of mRNA expression of fibroblast growth factor 2 (FGF2) in colorectal cancer (CRC) cell lines and in patients with metastatic colorectal cancer (mCRC) treated with FUFIRI or mIrOx (FIRE1).||http://abstracts.asco.org/176/AbstView_176_164113.html|
|7510||Prognostic significance of the proliferation signature in mantle cell lymphoma measured using digital gene expression in formalin-fixed paraffin-embedded tissue biopsies.||http://abstracts.asco.org/176/AbstView_176_163878.html|
|TPS7575||Rituximab, lenalidomide, and ibrutinib alone and combined with dose adjusted chemotherapy for patients with high risk diffuse large B-cell lymphoma.||
|7538||Feasibility of real-time cell-of-origin subtype identification by gene expression profile in the phase 3 trial of lenalidomide plus R-CHOP vs placebo plus R-CHOP in patients with untreated ||http://abstracts.asco.org/176/AbstView_176_162475.html|
|TPS7577||A phase 2 study of PNT2258 in patients with relapsed or refractory (r/r) diffuse large b-cell lymphoma (DLBCL): An initial report from the Wolverine study.||http://abstracts.asco.org/176/AbstView_176_165061.html|
|6010||Biomarkers and response to pembrolizumab (pembro) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).||http://abstracts.asco.org/176/AbstView_176_165708.html|
|e20014||The upregulation of FOXA2 transcription factor in RET rearranged lung adenocarcinoma.||http://abstracts.asco.org/176/AbstView_176_162380.html|
|e16023||PD1, PDL1, PDL2 tumor tissue (TT) expression as predictors of response to neoadjuvant chemotherapy (NAC) and outcome in bladder cancer (BC).||http://abstracts.asco.org/176/AbstView_176_167453.html|
|543||Prospective multicenter study of the impact of the Prosigna assay on adjuvant clinical decision-making in women with early stage breast cancer: which patients are the best candidates?||http://abstracts.asco.org/176/AbstView_176_166948.html|
|7547||Classification of diffuse large b-cell lymphoma (DLBCL) FFPE samples of the GELA LNH2003 program, using Lymph2Cx assay on the nCounter analysis system.||
|1536||T-cell inflamed phenotype gene expression signatures to predict clinical benefit from pembrolizumab across multiple tumor types.||http://abstracts.asco.org/176/AbstView_176_168432.html|
|3510||Clinical outcome and benefit of oxaliplatin in colon cancer according to intrinsic subtypes: Results from NRG Oncology/NSABP C-07.||http://abstracts.asco.org/176/AbstView_176_165798.html|
|1585||Male breast cancer: correlation between immunohistochemical subtyping and PAM50 intrinsic subtypes.||http://abstracts.asco.org/176/AbstView_176_167604.html|
|575||A retrospective study of SPAG5 expression and its clinical implications in > 8,000 patients of ER positive (ER+) breast cancer (BC): Genomic, transcriptomic and protein analysis.||http://abstracts.asco.org/176/AbstView_176_170849.html|
|569||Outcomes of single versus double hormone receptor positive breast cancer.||http://abstracts.asco.org/176/AbstView_176_169749.html|
|TPS623||OPTIMA (Optimal Personalised Treatment of early breast cancer usIng Multi-parameter Analysis): A prospective trial to validate the predictive utility and cost-effectiveness of gene expression test-directed chemotherapy decisions.||http://abstracts.asco.org/176/AbstView_176_169580.html|
|e23143||The genomic profile (GP) of early breast cancer (EBC): Daily practice analysis.||http://abstracts.asco.org/176/AbstView_176_167027.html|
|555||A test utilizing diagnostic and on-treatment biomarkers to improve prediction of response to endocrine therapy in breast cancer.||http://abstracts.asco.org/176/AbstView_176_168226.html|
For more information, please visit www.nanostring.com.
Doug FarrellVice President, Investor Relations & Corporate Communications email@example.com Phone: 206-602-1768
News Provided by Acquire Media